skingenix
Investors

Skingenix, Inc., a leader in dermal regeneration technologies located at Arcadia, California is currently pursuing a Phase II clinical study on MEBOÒ Wound Ointment (MEBO), a botanical drug product for patients with burn injuries, diabetic foot ulcers, and venous stasis ulcers. MEBO has been marketed in 24 countries outside the United States.

Skingenix, Inc. is open to potential investors who are interested in being a part of its growth, development, and success. Working together with motivated, talented, goal oriented, and highly experienced individuals at Skingenix with the guidance of a strong leadership of the management team, investors are encouraged to join the Skingenix group.


 
 
Copyright © 2009-2010 SKINGENIXWEB.COM. All Rights Reserved
The Skingenix, Inc. website has been designed for the audience worldwide. This website contains information about products which may or may not be available in different countries. In addition, the official approval or market clearance for indications of use may also differ per each country. Please consult individual country sites for approved uses and any applicable restrictions.The research data disclosed in this website is wholly for the purpose of scientific information exchange and is not intended for marketing or promotional uses.

Please note that Skingenix's drug product MEBO® Wound Ointment has not been approved by the Food and Drug Administration for any indication of use in the United States. It is currently under the status of Investigational New Drug (Phase II) for patients with burn injuries, venous stasis ulcers and diabetic foot ulcers.